The Blood Connection Incorporated

See schedule o blood processing storage and distribution: provision of blood components to healthcare providers: on a fee for service basis, preparation and distribution of blood components to hospitals, clinics, dialysis centers, blood banks, and blood fractionators. Goal: prepare blood components and distribute according to needs of healthcare clients. Maintain consistent (5-7 day supply) inventory of all types units of plasma distributed for blood derivative preparation. Cost containment for healthcare of blood components, for healthcare clients, number of patient beneficiaries, derived health benefits, lives saved.

See schedule o laboratory and cellular services: donated blood testing program: uses laboratory serologic, chemistry, and infectious disease assays to assess the suitability of donated blood, platelets and plasma. For donors detection of infectious disease for which donor may seek treatment. Positive public health consequences of disease detection, partner notification, exposure control.

Hematopoietic progenitor cell processing services: provides cellular therapy services including processing, cryopreservation, storage, infusion preparations for immunotherapy, and transplant for both autologous and matched related transplants for multiple myeloma, nhl and hodgkinis lymphoma. Provides transplant product preparation and shipment preparation to an outside facility upon request. The cryogenic storage services are provided free of charge for the first year. Goals: process 100% of requests for processing and infusions of hematopoietic progenitor cells and donor lymphocytes, offer services 24/7, provide same day turnaround for cd34+ flow cytometry analysis, and produce a product proven to be capable of engraftment. Cellular therapy collection services: provides cellular collection services for two healthcare providers. One, a biotechnology company (dendreon) applies its expertise in antigen identification, engineering and cell processing to produce an active cellular immunotherapy product called provenge (sipuleucel-t). Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. The blood connection collects mononuclear cells from prostate cancer patients deemed suitable by their physician and scheduled by dendreon. Post collection, the collected product is shipped to dendreon for further testing and processing; the final product is later transfused back to the patient at their transfusion center. The other provider is a cancer treatment institute affiliated with a local hospital system. The blood connection collects circulating bone marrow cells from patients in the remission phase of cellular cancers such as leukemia, lymphoma, and myeloma. Those collections, rich in hematopoietic progenitor cells, are then processed as described above. Additional program expenses include interest expenses and program related administrative expenses.